Abstract
Rosiglitazone: how should we be using this oral hypoglycaemic drug after studies indicating increased MI risk have resulted in changes in recommendations?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
